No new items were published in the sources we monitor on this date. The open consultations and hearings below remain current.
Federal Official Gazette
No updates.
ANS news
No updates.
Open public consultations
CP 176. Subject: preliminary recommendations against incorporating the technology covered by UAT No. 184 – Molecular DNA analysis; search for microdeletions by FISH (Fluorescent In Situ Hybridization); microsatellite instability (MSI), detection by PCR, paraffin block, DUT SUBITEM – 110.39 – Syndrome of clinically unrecognizable chromosomal abnormalities (array). Deadline: September 21 to October 10, 2026.
CP 178. Subject: preliminary recommendations against incorporating somatrogon and cabozantinib levomalate. Deadline: October 7 to 26, 2026.
Scheduled public hearings
AP 70. Subject: preliminary recommendations against incorporating somatrogon and cabozantinib levomalate, technologies submitted to public consultation 178. Date: Oct 16, 9:30 a.m. to 12:30 p.m.
Open public calls for input
The call for input directed to health plan operators’ ombudsman offices, concerning the resolution capacity of service channels and the monitoring provided for in RN No. 623/2024, is open until Oct 20.
Open public calls
There are no open public calls or targeted social participation procedures.
Other news
No updates.
Sources: Federal Official Gazette (DOU) and the ANS website. Press items link to the original article. This brief is for information only and does not constitute legal advice.